M
Merck & Co.
Merck develops and produces medicines, vaccines, biologic therapies and animal health products
About Merck & Co.
Merck & Co., Inc., headquartered in Kenilworth, N.J., is a global healthcare company dedicated to following the science to tackle some of the world's greatest health threats. The company focuses on developing innovative medicines and vaccines for a wide range of health issues, including cardiovascular disease, diabetes, and cancer. Merck serves a diverse clientele, including patients, healthcare professionals, and institutions worldwide. Operating in the pharmaceutical and biotechnology markets, Merck's business model revolves around extensive research and development (R&D) to create new treatments and therapies. The company generates revenue primarily through the sale of prescription medicines, vaccines, and animal health products. Additionally, Merck offers patient assistance programs to provide free medicines and vaccines to qualified patients, and professional resources through platforms like Merck Connect and Merck Manuals.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1891
- Headquarters
- Rahway, United States
- Listing
- IPO 1983
- Employees
- 44,700
- Open positions
- 789
- Dealroom signal
- 29.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology, Medical Devices, Health Platform
- Sector
- Biotech & Life Sciences, Personal Health, Diabetes, Risk Management, Developer Tools, Biotechnology, Oncology
- Business model
- Manufacturing
- Client focus
- b2b, b2c
- Investment activity
- 69 companies, latest May 2026
- Capital deployed
- $969M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Dec 2025 | $2B | — | Undisclosed | ↗ |
| POST IPO DEBT✓Debt | Sep 2025 | $6B | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Merck & Co. is 1M monthly website visits, up 25% over the last three months. Merck & Co.'s team declined 42.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 MEDtubeSocial eLearning platform for Health Professionals and Med Students |
Warsaw, Poland | Operational | 17 | — | — |
 MedtronicMedical technologies and therapies for chronic diseases |
Fridley, United States | Acquired | |||
 BayerGlobal enterprise with core competencies in the Life Science fields of health care and agriculture |
Leverkusen, Germany | Operational | |||
 CovidienGlobal Healthcare Products Leader |
Dublin, Ireland | Acquired | |||
 OrgenesisDeveloping and manufacturing cell-therapy solutions |
Tel Aviv-Yafo, Israel | Operational | |||
 CooeyCooey - Preventive and personalize health care. Automatically log your health data,store and share. |
Bengaluru, India | Operational | |||
 Omada HealthOnline programs combine world-class science, technology, and design to inspire and enable people everywhere to live free of chronic disease |
South San Francisco, United States | Operational | |||
 AstraZenecaBiopharmaceutical solutions for major global diseases |
Cambridge, United Kingdom | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Terns PharmaceuticalsFoster City, United StatesBiopharmaceutical company focused on discovering therapies that will improve the global disease burden
$6.7Bvaluation
Cidara TherapeuticsSan Diego, United StatesCidara Therapeutics is developing innovative therapies
$9.2Bvaluation
Solve TherapeuticsSan Diego, United StatesTargeted cancer therapies enhancing safety and precision
$480Mvaluation
Meta-fluxDublin, IrelandMeta-flux is an AI biologist for pharmaceutical drug development.
$7.9Mvaluation
Verona PharmaLondon, United KingdomFirst-in-class inhaled therapies for chronic respiratory diseases
$10Bvaluation
EkincareGafoornagar, IndiaA corporate health benefits platform
$60Mvaluation
HDBangkok, ThailandProviding affordable healthcare and surgeries in southeast asia
$31Mvaluation
Ambrosia BiosciencesBoulder, United StatesSmall molecule therapies for obesity and metabolic disorders, delivered orally
$400Mvaluation
PersonalisMenlo Park, United StatesContract research organization and genome-scale diagnostics services company specializing in genome guided medicine
$1.6Bvaluation
Modifi BiosciencesNew Haven, United StatesAt Modifi Bio, we are changing the oncology treatment paradigm by developing therapeutics that uniquely target specific acquired cancer cell DNA mutations
$17Mvaluation
Ash WellnessNew York City, United StatesPowered by Ash - Modern At-Home Diagnostics
→
Delfi DiagnosticsBaltimore, United StatesDetects cancer early, when it is most curable, using high precision non-invasive blood tests
$900Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
HHS Administration for Strategic Preparedness and Response
Series B and later2 investors entered at this stage
Scissortail Wealth Management
Wealth Management Partners
Other known investors2 additional known investors
ARCH Venture Partners
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Merck & Co. on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Merck & Co.’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.